Matching articles for "Dymista"

Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • January 23, 2023;  (Issue 1668)
The FDA has approved Ryaltris (Hikma), a fixed-dose combination nasal spray containing the H1-antihistamine olopatadine hydrochloride (Patanase, and generics) and the corticosteroid mometasone furoate...
The FDA has approved Ryaltris (Hikma), a fixed-dose combination nasal spray containing the H1-antihistamine olopatadine hydrochloride (Patanase, and generics) and the corticosteroid mometasone furoate (Nasonex 24 HR Allergy, and generics), for treatment of seasonal allergic rhinitis symptoms in persons ≥12 years old. Ryaltris is the second intranasal antihistamine/corticosteroid combination to be approved for this indication; azelastine 0.1%/fluticasone propionate (Dymista, and generics), which is approved for use in persons ≥6 years old, was the first. Both products are available only by prescription.
Med Lett Drugs Ther. 2023 Jan 23;65(1668):12-4 | Show Full IntroductionHide Full Introduction

Drugs for Allergic Rhinitis and Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • April 19, 2021;  (Issue 1622)
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table...
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2021 Apr 19;63(1622):57-64 | Show Full IntroductionHide Full Introduction

Comparison Table: Some Oral Drugs for Allergic Rhinitis (online only)

   
The Medical Letter on Drugs and Therapeutics • April 19, 2021;  (Issue 1622)
...
View the Comparison Table: Some Oral Drugs for Allergic Rhinitis
Med Lett Drugs Ther. 2021 Apr 19;63(1622):e63-5 | Show Full IntroductionHide Full Introduction

Comparison Table: Some Nasal Sprays for Allergic Rhinitis (online only)

   
The Medical Letter on Drugs and Therapeutics • April 19, 2021;  (Issue 1622)
...
View the Comparison Table: Some Nasal Sprays for Allergic Rhinitis
Med Lett Drugs Ther. 2021 Apr 19;63(1622):e66-71 | Show Full IntroductionHide Full Introduction

Drugs for Allergic Disorders

   
The Medical Letter on Drugs and Therapeutics • May 8, 2017;  (Issue 1520)
Allergic rhinitis can be classified as seasonal, perennial, or episodic. It is often associated with allergic conjunctivitis, rhinosinusitis, and asthma. H1-ANTIHISTAMINES — Oral – Oral...
Allergic rhinitis can be classified as seasonal, perennial, or episodic. It is often associated with allergic conjunctivitis, rhinosinusitis, and asthma.

H1-ANTIHISTAMINES — Oral – Oral second-generation H1-antihistamines are the preferred first-line treatment for relief of the itching, sneezing, and rhinorrhea that characterize mild-to-moderate allergic rhinitis. They are less effective for nasal congestion.
Med Lett Drugs Ther. 2017 May 8;59(1520):71-82 | Show Full IntroductionHide Full Introduction

Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis (online only)

   
The Medical Letter on Drugs and Therapeutics • May 8, 2017;  (Issue 1520)
...
View the Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis
Med Lett Drugs Ther. 2017 May 8;59(1520):e85-90 | Show Full IntroductionHide Full Introduction

Drugs for Allergic Disorders

   
The Medical Letter on Drugs and Therapeutics • May 1, 2013;  (Issue 129)
The use of drugs to prevent and control symptoms of allergic disorders can be optimized when patients avoid exposure to specific allergens and/or environmental conditions that trigger or worsen their...
The use of drugs to prevent and control symptoms of allergic disorders can be optimized when patients avoid exposure to specific allergens and/or environmental conditions that trigger or worsen their symptoms.
Treat Guidel Med Lett. 2013 May;11(129):43-52 | Show Full IntroductionHide Full Introduction

Azelastine/Fluticasone Propionate (Dymista) for Seasonal Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • October 29, 2012;  (Issue 1402)
The FDA has approved a nasal spray fixed-dose combination (Dymista – Meda) of the H1-antihistamine azelastine (Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate (Flonase, and...
The FDA has approved a nasal spray fixed-dose combination (Dymista – Meda) of the H1-antihistamine azelastine (Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate (Flonase, and generics) for treatment of seasonal allergic rhinitis (SAR) in patients ≥12 years old who need both medications for symptomatic relief. It is the first nasal spray to be approved in the US that contains both an H1-antihistamine and a corticosteroid.
Med Lett Drugs Ther. 2012 Oct 29;54(1402):85-7 | Show Full IntroductionHide Full Introduction